MedPath

GENETHON

GENETHON logo
🇫🇷France
Ownership
Private
Established
1990-01-01
Employees
501
Market Cap
-
Website
http://www.genethon.fr

Clinical Trials

26

Active:12
Completed:5

Trial Phases

3 Phases

Phase 1:18
Phase 2:2
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials

Phase 1
18 (85.7%)
Phase 2
2 (9.5%)
Not Applicable
1 (4.8%)

Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

Phase 2
Recruiting
Conditions
Crigler-Najjar Syndrome
Interventions
First Posted Date
2024-07-24
Last Posted Date
2024-12-03
Lead Sponsor
Genethon
Target Recruit Count
3
Registration Number
NCT06518005
Locations
🇫🇷

Hopital Antoine BECLERE, Clamart, France

Natural History of Duchenne Muscular Dystrophy

Recruiting
Conditions
Duchenne Muscular Dystrophy
First Posted Date
2019-03-20
Last Posted Date
2022-09-07
Lead Sponsor
Genethon
Target Recruit Count
100
Registration Number
NCT03882827
Locations
🇫🇷

University Hospital of Bordeaux, Bordeaux, France

🇫🇷

Brest University Hospital Centre, Brest, France

🇫🇷

Hopital Femme Mere Enfant, Bron, France

and more 6 locations

Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I

Active, not recruiting
Conditions
LGMD2I
First Posted Date
2019-02-15
Last Posted Date
2023-04-06
Lead Sponsor
Genethon
Target Recruit Count
52
Registration Number
NCT03842878
Locations
🇩🇰

Pr John Vissing, Copenhagen, Denmark

🇫🇷

Dr Tanya Stojkovic, Paris, France

🇬🇧

Pr Volker Straub, Newcastle, United Kingdom

Gene Therapy for Severe Crigler Najjar Syndrome

Not Applicable
Recruiting
Conditions
Crigler-Najjar Syndrome
First Posted Date
2018-03-15
Last Posted Date
2023-03-28
Lead Sponsor
Genethon
Target Recruit Count
17
Registration Number
NCT03466463
Locations
🇫🇷

Hopital Antoine BECLERE, Clamart, France

🇮🇹

ASST Papa Giovanni XXIII, Bergame, Italy

🇮🇹

Azienda Ospedaliera Universitaria Federico II, Napoli, Italy

and more 1 locations

Gene Therapy for X-linked Chronic Granulomatous Disease

Phase 1
Active, not recruiting
Conditions
X-Linked Chronic Granulomatous Disease
First Posted Date
2016-05-02
Last Posted Date
2023-04-06
Lead Sponsor
Genethon
Target Recruit Count
3
Registration Number
NCT02757911
Locations
🇫🇷

Hôpital Necker Enfants Malades, Paris, France

  • Prev
  • 1
  • 2
  • 3
  • Next

News

Hansa Biopharma's Imlifidase Shows Promise in Guillain-Barré Syndrome and Anti-GBM Disease

• Hansa Biopharma announced positive Phase 2 results for imlifidase in Guillain-Barré Syndrome (GBS), showing rapid functional improvement in patients. • The company completed enrollment in the pivotal Phase 3 GOOD-IDES-02 trial of imlifidase for anti-glomerular basement membrane (anti-GBM) disease. • A Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome has been initiated in collaboration with Genethon. • Hansa Biopharma anticipates submitting a Biologics License Application (BLA) to the FDA for imlifidase in kidney transplantation in late 2025.

Imlifidase Shows Promise in Guillain-Barré Syndrome and Expands Gene Therapy Access

• Phase 2 data indicates imlifidase, combined with IVIg, significantly improves motor function and accelerates recovery in Guillain-Barré Syndrome (GBS) patients. • An indirect comparison showed GBS patients treated with imlifidase and IVIg returned to independent walking six weeks sooner than those treated with IVIg alone. • Hansa Biopharma and Genethon initiated a Phase 2 trial using imlifidase as a pretreatment to broaden access to gene therapy for Crigler-Najjar syndrome. • Hansa Biopharma completed enrollment in a Phase 3 trial of imlifidase for anti-GBM disease, with data expected in 2025.

Genethon's GNT0004 Gene Therapy Shows Promise in Duchenne Muscular Dystrophy Trial

Genethon's GNT0004, a gene therapy for Duchenne muscular dystrophy (DMD), demonstrates positive initial results in a Phase 1/2/3 clinical trial, showing stable or improved motor function in treated patients.

Genethon's AAV Gene Therapy GNT0004 Shows Promise in Duchenne Muscular Dystrophy Trial

Genethon's GNT0004 gene therapy demonstrated good tolerability in boys with Duchenne muscular dystrophy when combined with transient immunological prophylactic treatment.

© Copyright 2025. All Rights Reserved by MedPath